Literature DB >> 15274319

High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines.

Akio Hiraki1, Nobuharu Fujii, Tomoyuki Murakami, Katsuyuki Kiura, Keisuke Aoe, Hiromichi Yamane, Kozo Masuda, Tadashi Maeda, Kazuro Sugi, Zbigniew Darzynkiewicz, Mitsune Tanimoto, Mine Harada.   

Abstract

Loss or down-regulation of HLA expression has been demonstrated in various types of solid tumors and is considered to be one of the mechanisms of tumor immunoescape. The effectiveness of immunotherapy using tumor-specific antigens (TSA) largely depends on the expression of the appropriate HLA class I alleles on the tumor cells. We analyzed the allele-specific HLA class I surface expression of six lung cancer cell lines using a broad panel of allele-specific monoclonal antibodies, as well as the effect of IFN-gamma on HLA expression. Flow cytometric analysis displayed a wide range, from minimal to a high degree of expression of monomorphic HLA class I among the studied cell lines. Allele-specific loss or down-regulation of HLA also was observed in 5 out of 6 cell lines. Our results suggest that lung cancer patients considered for specific immunotherapy should be examined with respect to the expression of specific HLA class I allele binding the TSA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15274319

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Sequence and Phylogenetic Analysis of the Untranslated Promoter Regions for HLA Class I Genes.

Authors:  Veron Ramsuran; Pedro G Hernández-Sanchez; Colm O'hUigin; Gaurav Sharma; Niamh Spence; Danillo G Augusto; Xiaojiang Gao; Christian A García-Sepúlveda; Gurvinder Kaur; Narinder K Mehra; Mary Carrington
Journal:  J Immunol       Date:  2017-02-01       Impact factor: 5.422

Review 2.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

3.  Exploring the mechanism and experimental verification of puerarin in the treatment of endometrial carcinoma based on network pharmacology and bioinformatics analysis.

Authors:  Zhiheng Lin; Xiaohui Sui; Wenjian Jiao; Ying Wang; Junde Zhao
Journal:  BMC Complement Med Ther       Date:  2022-06-07

4.  Impaired cell surface expression of HLA-B antigens on mesenchymal stem cells and muscle cell progenitors.

Authors:  Adiba Isa; Jan O Nehlin; Hardee J Sabir; Tom E Andersen; Michael Gaster; Moustapha Kassem; Torben Barington
Journal:  PLoS One       Date:  2010-05-28       Impact factor: 3.240

5.  Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.

Authors:  Marco A J Iafolla; Cindy Yang; Vinod Chandran; Melania Pintilie; Quan Li; Philippe L Bedard; Aaron Hansen; Stephanie Lheureux; Anna Spreafico; Albiruni A Razak; Sevan Hakgor; Amanda Giesler; Trevor J Pugh; Lillian L Siu
Journal:  JNCI Cancer Spectr       Date:  2020-12-29

6.  Cell surface expression level variation between two common Human Leukocyte Antigen alleles, HLA-A2 and HLA-B8, is dependent on the structure of the C terminal part of the alpha 2 and the alpha 3 domains.

Authors:  Christoffer Dellgren; Jan O Nehlin; Torben Barington
Journal:  PLoS One       Date:  2015-08-10       Impact factor: 3.240

7.  HLA Class I Allele Frequencies in Southern Iranian Women with Breast Cancer.

Authors:  Mahboobeh Razmkhah; Abbas Ghaderi
Journal:  Iran J Basic Med Sci       Date:  2013-02       Impact factor: 2.699

Review 8.  Monalizumab: inhibiting the novel immune checkpoint NKG2A.

Authors:  Thorbald van Hall; Pascale André; Amir Horowitz; Dan Fu Ruan; Linda Borst; Robert Zerbib; Emilie Narni-Mancinelli; Sjoerd H van der Burg; Eric Vivier
Journal:  J Immunother Cancer       Date:  2019-10-17       Impact factor: 13.751

Review 9.  Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.

Authors:  Kei Kunimasa; Taichiro Goto
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

10.  Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.

Authors:  Nicholas McGranahan; Rachel Rosenthal; Crispin T Hiley; Andrew J Rowan; Thomas B K Watkins; Gareth A Wilson; Nicolai J Birkbak; Selvaraju Veeriah; Peter Van Loo; Javier Herrero; Charles Swanton
Journal:  Cell       Date:  2017-10-26       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.